Phaseline

Companies › CytoMed Therapeutics Pte

CytoMed Therapeutics Pte: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2
NKG2DL-targeting CAR-T cell therapy using allogeneic gamma-delta T cells
NKG2DPhase 1CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05302037Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2Phase 1CancerOncologyDec 2026

From the company's SEC filings

Cash of 2m SGD on 2025-12-31; operating cash outflow about 4m SGD a year; runway about 7 months at that burn, to Jul 2026

Targets

NKG2D (1)

Companies with the same targets

Celyad Oncology

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.